Note 1: Segment Information continued The table reconciles statutory results for key line items to the segment report. Statutory results Amortisation of acquired IP Non-recurring items related to CSL Vifor acquisition Net gain on business disposal Tax impacts of the adjustments Segment results Year ended 30 June (US$m) 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Gross profit 8,079 7,671 364 301 — 34 — — — — 8,443 8,006 Selling and marketing expenses (1,616) (1,573) — — — 17 — — — — (1,616) (1,556) Research and development expenses (1,359) (1,430) — — — 2 — — — — (1,359) (1,428) General and administrative expenses (1,000) (856) — — — 31 — — — — (1,000) (825) Net gain on business disposals 30 — — — — — (30) — — — — — EBIT / Underlying EBIT 4,134 3,812 364 301 — 84 (30) — — — 4,468 4,197 Profit before tax 3,724 3,375 364 301 — 84 (30) — — — 4,058 3,760 NPAT / NPATA 3,136 2,714 364 301 — 84 (30) — (57) (61) 3,413 3,038 - NPAT / NPATA attributable to CSL shareholders 3,002 2,642 295 241 — 74 (30) — (48) (50) 3,219 2,907 - NPAT / NPATA attributable to noncontrolling interests 134 72 69 60 — 10 — — (9) (11) 194 131 Basic earnings per share / NPATA per share (US$) 6.20 5.47 0.61 0.50 — 0.15 (0.06) — (0.10) (0.10) 6.65 6.02 Other segment information CSL Behring CSL Seqirus CSL Vifor Consolidated Entity US$m US$m US$m US$m Segment assets and liabilities 2025 2024 2025 2024 2025 2024 2025 2024 Segment assets 24,495 23,635 4,674 4,403 10,235 9,984 39,404 38,022 Segment liabilities 14,948 15,373 1,375 1,415 1,674 1,833 17,997 18,621 Segment assets and liabilities disclosed above exclude intercompany receivables, payables and investments in subsidiaries which have been eliminated. Segment cash flow information Cash payments for property, plant and equipment (PPE) 505 615 119 212 12 22 636 849 Cash payments for intangibles 114 165 150 156 98 88 362 409 Cash payments for PPE during the year ended 30 June 2025 include investment made into expanding the manufacturing capacity at the Broadmeadows site, advancing the Group's global asset management program and developing a new cell-based influenza vaccine manufacturing facility in Tullamarine, Australia. In addition, cash payments for intangibles during the year ended 30 June 2025 include development milestone payments related to the Group's licensing arrangements, including with Arcturus Therapeutics Holdings Inc, as well as payments made for software. 98 Notes to the Financial Statements 98 Financial Report
RkJQdWJsaXNoZXIy MjE2NDg3